Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SPR Therapeutics Inc.

www.sprtherapeutics.com

Latest From SPR Therapeutics Inc.

SPR's Peripheral Nerve Stimulator Relieves Post-Amputation Pain

SPR Therapeutics' Sprint percutaneous peripheral nerve stimulator proved safe and effective at reducing pain in post-amputation patients in a new 28-patient randomized study.

Research & Development Clinical Trials

Market Intel: Peripheral Nerve Stim Players Edge Out Innovative Paths

While demand for spinal cord stimulation (SCS) devices used in pain management continues to expand at double-digit rates, a small but growing number of highly innovative companies that develop stimulators to specifically target peripheral nerve pain is creating excitement among pain doctors looking for better options to treat an intractable population that's seen little success with standard therapy. With millions of people worldwide suffering from low back pain, severe headaches and migraines, neck pain and other chronic pain, the demand for safe, effective, percutaneously-placed devices remains high. In this article, we'll highlight emerging companies working on PNS devices and provide insights from pain physicians on the pros and cons of these devices.

Neurology Commercial

Execs On The Move, March 2017

Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Leadership BioPharmaceutical

SPR Therapeutics: Peripheral Nerve Stimulation To Treat Pain

The Smartpatch from SPR Therapeutics LLC stimulates the peripheral nerves that carry the pain signal to the central nervous system. The minimally invasive and reversible neurostimulation system can remain implanted for up to 60 days, offering therapy to patients in acute as well as chronic pain.

Medical Device Innovation
See All

Company Information

  • Industry
  • Medical Devices
    • Implantable Devices
    • Surgical Equipment & Devices
      • Minimally or Less Invasive
  • Therapeutic Areas
  • Musculoskeletal & Connective Tissue Disorders
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • SPR Therapeutics Inc.
  • Senior Management
  • Maria Bennett, Pres. & CEO
    Joseph Boggs, PhD, SVP, R&D
    Dave Youngberg, VP, Sales
    Mark Stultz, SVP, Mkt. Dev.
  • Contact Info
  • SPR Therapeutics Inc.
    Phone: (216) 378-9108
    22901 Millcreek Blvd.
    Ste. 110
    Cleveland, OH 44122
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register